Takeda Canada Secures REVESTIVE Reimbursement in BC
TORONTO, ON, Canada – May 5, 2026 Takeda Canada Inc. has announced that REVESTIVE® (teduglutide for injection) will now...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TORONTO, ON, Canada – May 5, 2026 Takeda Canada Inc. has announced that REVESTIVE® (teduglutide for injection) will now...
WESTON, FLORIDA, April 27, 2026 Apotex has secured U.S. Food and Drug Administration (FDA) approval for its generic Infuvite®...
WESTON, FLORIDA, USA, April 14, 2026 Apotex Corp., in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma...
